Answers are grounded in this paper and cite their sources.
Demonstrates RAS genotype's limited predictive power on MAPK signaling in multiple myeloma, suggesting new approaches.
Key Points NRAS and KRAS mutations lead to different downstream transcriptional signatures and patient prognoses under current myeloma therapies. RAS genotype alone does not strongly predict degree of active MAPK signaling, suggesting alternate precision medicine approaches are needed.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: